Objectives: (a) Determine the demographic and medical risk factors for patients who presented with unilateral idiopathic sudden sensorineural hearing loss (ISSNHL); (b) identify treatments that patients underwent; (c) evaluate the adequacy of follow-up and compliance with long-term hearing rehabilitation.
| INTRODUCTION
Idiopathic unilateral sudden sensorineural hearing loss (ISSNHL) is a rapid onset of hearing loss from cochlear or retrocochlear origins. Unilateral ISSNHL is characterized by subjective and objective hearing impairment with decrease in hearing thresholds of ≥30 dB (dB) in three or more consecutive frequencies on dedicated audiometric testing. 1 Global incidence of ISSNHL is estimated to be 5 to 20/100000 persons. [2] [3] [4] In the United States, 4000 new cases are reported each year. 3 Viral infections, cochlear ischemia, metabolic derangement, and autoimmune processes have all been proposed as potential etiologies. 3, 5 Treatment for unilateral ISSNHL is aimed at the recovery of hearing thresholds. 2 Various treatment options, including oral and intratympanic (IT) steroids, diuretics, antiviral, and hyperbaric oxygen therapy, have been studied in case reports, retrospective reviews, and randomized controlled trials. 1, 2, [5] [6] [7] In the American Academy of
Otolaryngology-Head and Neck Surgery (AAO-HNS) clinical practice guideline (CPG) on sudden hearing loss, systemic steroids were proposed as a first-line agent for ISSNHL. 1 IT steroid injections were determined to be a useful adjunct for select patients. 7 For individuals with partial or no hearing recovery, long-term hearing amplification is recommended. Options for hearing amplification include conventional hearing aids, contralateral routing of signal (CROS) devices, osseointegrated bone conduction devices, and cochlear implants (CI). [8] [9] [10] [11] [12] Prior studies suggest the need for ongoing otolaryngologic, audiologic, and psychosocial evaluations for patients with ISSNHL. 1 While the treatment efficacy for steroids has been well described, less is known about the adequacy of follow-up and patient compliance with long-term hearing amplification. With two decades of experience, we set out to systematically characterize long-term hearing outcomes in patients with unilateral ISSNHL. Beyond providing descriptive information on demographics and medical risk factors, our analysis sought to provide a summary of treatment modalities and duration of followup. We also sought to characterize patients' perception of hearing recovery and their audiometric outcomes. These analyses offer insight into how patients with unilateral ISSNHL recover, and data obtained in this study may be used to inform patient expectations or guide long-term treatment strategies for unilateral ISSNHL.
| MATERIALS AND METHODS

| Study population
This study was a retrospective review of clinical data. Individuals 18 years and older who presented to the University of Michigan between January 1998 and December 2017 were identified. Consecutive data were reviewed. Patients met the following inclusion criteria: a history of unilateral sudden hearing loss of ≥30 dB in three or more consecutive frequencies (confirmed on pure tone audiometry)
without an identifiable cause (ie, normal imaging, no identified middle ear infection, or history of trauma). We excluded patients who presented with conductive hearing loss, gradual hearing loss, congenital The severity of hearing loss was categorized based on the PTA.
Normal hearing (<26 dB), mild (≥26-40 dB), moderate (41-70 dB), severe (71-90 dB), or profound hearing loss (≥91 dB) were defined accordingly. In addition, the shape of the pretreatment audiogram has been shown to prognosticate hearing recovery after ISSNHL. 13 In a recent review by Kuhn et al in 2011, low-and mid-frequency sensorineural hearing loss was associated with better recovery compared to flat or a down-sloping audiogram. 14 In our study, we described an audiogram as "up-sloping" (ie, hearing loss in the low-or midfrequencies rising to normal hearing), "down-sloping" (ie, hearing loss in the high-frequencies), "flat" (ie, hearing loss across all frequencies), or "normal hearing in low-and high-frequencies." Audiogram shapes that did not fit with these descriptions were categorized as "other."
The recommended treatment for unilateral ISSNHL was recorded. Subjective hearing improvement was defined as patient-reported recovery at the most recent clinic visit. This was further classified as patient reporting of "no improvement," "partial improvement," or "complete hearing recovery" as compared to the patient's perceived baseline (pre-loss) hearing. To assess audiometric outcomes, we employed the Siegel criteria. 15 The Siegel audiometric recovery criteria is an accepted classification system and has been used in the ISSNHL literature. 15, 16 We defined audiometric improvement as a PTA improvement of ≥15 dB in the first posttreatment audiogram. In this study we also included individuals who achieved normal hearing after treatment. Treatments are defined as "primary" if they were the first recommendations we provided. We defined subsequent therapy as "additional treatment." The duration of follow-up was determined from the date of initial evaluation to the date of the most recent otolaryngology or audiology clinic visit at our institution.
| Analysis
Demographics, medical risk factors, treatment modality, and audiometric outcomes were analyzed using descriptive statistics. The STATA 15 statistical software was used for all analyses (StataCorp, College Station, Texas). An independent student's t test was used to compare pretreatment and posttreatment audiometric variables.
Two subgroup analyses were performed. First, we compared audiometric data in patients who underwent prior treatments at an outside hospital vs those who were never treated before being seen at our institution for evaluation. Next, we performed a subgroup analysis on treatment modalities in patients who had hearing improvement by the Siegel criteria vs those who did not show improvement. A P value <.05 was considered statistically significant for all analyses.
3 | RESULTS
| Demographic and audiometric data
At the University of Michigan, 2387 patients met initial search criteria and were evaluated for asymmetric/unilateral hearing loss between January 1998 and December 2017. Most patients were excluded due to progressive, non-acute hearing loss (n = 1029, 43.1%), nonaudiologic complaints (ie, vestibular dysfunction, nasal congestion; n = 859, 36.0%), or conductive and mixed hearing loss (n = 351, 14.7%).
Of note, 90 (3.8%) were excluded due to discovery of a middle ear or retrocochlear lesion that presented as unilateral SSNHL.
Two hundred-four patients (8.5% of 2387 patients) met criteria for unilateral ISSNHL (mean age: 55.4 years, 52.5% female, and 83.3% Caucasian). Demographics and medical comorbidities are summarized in Table 1 . Most patients (82.8%) underwent imaging to formally rule out an inner ear or retrocochlear lesion. Approximately 16% of patients did not undergo imaging due to refusal or inability to tolerate MRI scans.
In the first subgroup analysis, patients were stratified into those who received initial treatment at an outside facility (n = 75, 36.8%) vs those who did not (n = 129, 63.2%). Most (60%) patients who underwent prior treatments at an outside facility had hearing loss for at least 31 days by the time they were seen in our institution. In contrast, 59.7% of patients who received no prior treatment presented to our institution with reported hearing loss onset for ≤10 days. Treatment with oral steroids was the most commonly prescribed modality in patients who were treated at local facilities. The follow-up duration for the overall cohort was 17.9 months. Follow-up duration between the two subgroups were similar (P = .344).
For subsequent analyses, we analyzed patients who were not treated prior to our evaluation (n = 129). We excluded patients who received previous treatments (n = 75) due to difficulty with extracting treatment details from outside clinical records. Our analysis demonstrated that the two subgroups were similar in terms of demographic and medical characteristics. In the subgroup of patients who received treatment after they were seen by our clinicians, we noted PTA improvement from 61.9 to 45.6 dB (P < .001; 
| Treatment modality and follow-up
Treatment recommendations are summarized in Table 3 for the 129 patients who presented to our institution without prior treatment.
T A B L E 1 Demographic, medical comorbidities, and symptoms of patients who presented with unilateral idiopathic sudden sensorineural hearing loss use either a CROS or bilateral CROS (BiCROS) hearing device as a primary therapy. Similarly, bone-anchored hearing aids or cochlear implants (CIs) were not recommended as first-line treatments. Two patients (1.6%) received no further treatment recommendations. In both cases, hearing loss was deemed to be mild by the patient, and no further therapy was pursued.
One hundred four (81%) patients required additional recommendations after the initial therapy (Table 3) . In contrast with primary study, a CI was recommended to two patients (1.9%) after they did not respond to primary treatment. In both cases, the patients did not seek further evaluation for a CI.
In our second subgroup analysis, we stratified the cohort into patients who had improved hearing (ie, defined by PTA improvement of ≥15 dB or normal hearing in the first posttreatment audiogram per Siegel criteria; n = 55) vs those who did not (n = 74, Table 4 ). 15 Baseline audiometric characteristics were poorer among patients with no improved hearing. As expected, posttreatment audiograms were significantly better in patients with improved hearing (P < 
| DISCUSSION
Unilateral ISSNHL is a debilitating condition that poses considerable diagnostic and treatment challenges for otolaryngologists and audiologists. Treatments for unilateral ISSNHL have been extensively reviewed in case reports, retrospective studies, and randomized controlled trials. [1] [2] [3] [4] [5] [6] [7] The AAO-HNS CPG supports early administration of systemic steroids followed by salvage IT steroid injections. Beyond treatments with steroids, the CPG advocates follow-up with otolaryngologists and audiologists and repeat audiometric assessment within 6 months of hearing loss diagnosis. While the treatment efficacy for steroids has been well described, less is known about the adequacy of follow-up and patient compliance with hearing amplification. In reviewing two decades of data, we addressed these questions with a large cohort of patients with unilateral ISSNHL. We used the Siegel criteria for defining hearing recovery. 15 The Siegel criteria was used in recent ISSNHL literature 16 and served as a useful means to quantify treatment outcomes. In the present study, we also excluded patients (n = 75) who were treated at local facilities prior to our evaluation. Our rationale for this exclusion was to examine a uniform cohort comprised of patients who were evaluated and treated at a single institution with consistent medical documentation both pretreatment and posttreatment.
In our study, posttreatment audiograms were obtained~50 days after the pretreatment audiograms. Within this period, we observed audiometric improvement in 44.4% (n = 55) of patients. In reviewing their most recent audiograms, PTA was 51.5 dB and WRS improvement was modest (Table 2) . About 60% of our cohort underwent treatment with oral steroids. Furthermore, 19.4% underwent dual therapy with oral followed by salvage IT steroid injections. Only nine patients (7.2%) underwent IT injections alone. These nine patients had underlying medical comorbidities (most commonly, uncontrolled diabetes) that precluded them from systemic steroid use. Among patients who achieved audiometric recovery, oral steroids followed by conventional hearing aids were the two most common recommendations.
Methods for hearing amplification were recommended to 47.3% of patients. Conventional hearing aids were the most popular recommen- Cochlear implantation is an emerging option for sudden hearing loss and has been investigated in recent clinical trials. 18 During the study period (January 1998 to December 2017), patients with unilateral ISSNHL did not meet the United States Food and Drug Administration criteria for a CI. 19 It is thus not surprising that a CI was offered to only two patients in our cohort, after they had failed medical therapies. Both patients did not pursue a CI due to a lack of interest in a surgical option and difficulty with insurance approvals. Since the conclusion of this study period,~20 patients were recommended to consider a CI for an "off label" indication at our institution. Additionally, 21 Altogether, our data corroborate with existing literature and the AAO-HNS CPG in suggesting ongoing needs for longterm follow up and medical, and possibly surgical interventions, for hearing restoration. 22 The strengths and limitations of the study should be considered.
First, all patients in this cohort were treated and followed up by a consistent group of clinical providers at a single tertiary care institution.
Their clinical care was carefully documented in the electronic medical record system. However, although this is one of the larger series to examine long-term outcomes of unilateral ISSNHL, our study is retrospective and cannot support causal inferences. Second, there are variations in our treatment protocols by individual otolaryngologists and audiologists. For example, our oral steroid regimen ranged from a 7-day course to a 14-day course and was followed by various permutations of slow vs fast steroid taper and doses. The publication of the AAO-HNS CPG on sudden hearing loss calls for standardization in treatment paradigm and hopes to address these practice variations in the future. Third, despite our effort to examine a longitudinal cohort over 20 years, the follow-up duration in this study was short. To better evaluate long-term outcomes, longitudinal studies are required to ensure adequate length of follow-up. Along the same lines, future studies are needed to better understand potential patient factors and systemic barriers to reduced follow-up and poor patient compliance with hearing amplification.
| CONCLUSION
In our cohort of patients who presented to a tertiary care medical institution with unilateral ISSNHL, we observed a 44.4% audiometric recovery on pure tone audiometry and 61.2% of patient-reported hearing improvement. Most patients at our institution experienced some degree of hearing recovery, but many had persistent hearing loss after the initial episode of ISSNHL. Over the course of 20 years, the average follow-up duration was only 18 months. Despite a 44% audiometric recovery rate, long-term hearing amplification was recommended in less than half of the cohort and patient compliance with hearing amplification devices was poor. Future studies are needed to better assess long-term audiometric outcomes and to determine factors that contribute to poor follow-up patterns and compliance with hearing rehabilitation strategies.
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